B of A Securities analyst George Staphos downgrades Boise Cascade (NYSE:BCC) from Neutral to Underperform.
AstraZeneca Expands U.S. Manufacturing Footprint With $300M Investment To Accelerate Ambitions In Next-Generation Cell Therapy Discovery And Development
New facility in Rockville, Maryland will focus on manufacturing for critical cancer trials and launch of its commercial cell therapy platformsAstraZeneca is investing $300 million in a state-of-the-art facility in
